You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
Based on the results of the new studies, the Norwegian company is positioning its calprotectin test as an alternative to conventional ELISAs.
The researchers said that their approach using 11 plasma protein biomarkers could enable early detection of ovarian cancers and reduce unneeded, associated surgeries.
Over the next three years, Immunovia and its partners will use the firm's Immray PanCan-d assay to screen 6,000 diabetes patients for pancreatic cancer.
The sepsis diagnostics market heated up during the year, with FDA clearances for a handful of tests, growing investor interest, and R&D advances in the field.
CEO Anders Rylander said the company will initially market its DiviTum assay for breast cancer cases, though it could be used to monitor cell proliferation in all cancer types.